Jon Andrew Ferlmann, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 6701 Paw Paw Ave, Coloma, MI 49038 Phone: 269-463-3600 |
Dr. Michael E Mayle, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 6701 Paw Paw Ave, Coloma, MI 49038 Phone: 269-463-3600 Fax: 269-463-0013 |
Mr. Edwin Keith Newington, PA-C Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 6701 Paw Paw Ave, Coloma, MI 49038 Phone: 269-468-6430 Fax: 269-468-0013 |
News Archive
Inari Medical, Inc. announced today that it has closed a $12.4 million Series B venture capital financing. The financing was led by members of the board of directors and returning investors Versant Ventures and US Venture Partners. The round also included participation by several medical device industry veterans.
Obese people support lifestyle-change interventions, rather than those that purely promote weight loss. Researchers writing in BioMed Central's open access journal BMC Public Health interviewed 142 obese people about their opinions on interventions ranging from gastric bands to legal regulation, finding that non-commercial, non-stigmatizing techniques were preferred.
Modern Healthcare: "The Senate is expected to vote on a fiscal 2010 Defense appropriations bill by this weekend that would extend a health insurance subsidy for laid-off workers through February 2010. The House has approved the subsidy extension for the COBRA program, which was tucked into the $636.3 billion Defense appropriations bill."
A bedside electronic device that measures eye movements can successfully determine whether the cause of severe, continuous, disabling dizziness is a stroke or something benign, according to results of a small study led by Johns Hopkins Medicine researchers.
3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.
› Verified 1 days ago